在炎症性肠道疾病中,与疾病活动相关的血液蛋白质签名与疾病活动有关
Maëva Veyssière1, Nassim Hammoudi2,3, Lionel Le Bourhis2
1Université Paris Cité, INSERM U976, Paris, France.
Journal of Crohn's & colitis
|September 8, 2025
概括
炎症性肠病 (IBD) 的复发和生物治疗失败与特定的血液蛋白质签名有关. 识别这些生物标志物可以指导克罗恩病 (CD) 和性结肠炎 (UC) 的个性化疗法.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),呈现异质的临床过程,对生物疗法的反应有所变化.
- 术后CD复发是一个重要的临床挑战,即使有预防性治疗.
- 识别与复发和治疗结果相关的炎症调解者对于开发个性化治疗策略至关重要.
研究的目的:
- 分析IBD患者的血清炎症蛋白标志.
- 为了确定与术后CD复发相关的生物标志物.
- 调查与生物治疗反应和IBD失败相关的蛋白质特征.
主要方法:
- 来自两个潜在队列的血清样本的蛋白质组分析:REMIND (术后CD) 和ELYP (生物药物上的IBD活跃患者).
- 血清样本在基线和多个随访时间点 (6个月,14周,52周) 收集.
- 与临床结果相关的蛋白质水平,包括疾病复发,严重程度和治疗反应.
主要成果:
- 高水平的IFN-γ,CXCL9和MMP-10与CD复发和严重程度有关.
- 手术前的MMP-10水平预测了严重的复发.
- 生物治疗反应与特定蛋白质变化有关:抗TNF的CXCL9和ustekinumab的OSM/TGFα. 在CD中,IFN-γ和CXCL9的含量高于UC.
结论:
- 鲜明的炎症性血液蛋白质特征与IBD的术后复发和生物治疗失败有关.
- 确定的主要生物标志物包括IFN-γ,CXCL9,MMP-10和OSM.
- 这些发现支持个性化治疗方法,可能涉及针对多个炎症途径的组合疗法.
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
604
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
604
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
844
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
844
01:30Inflammatory Bowel Disease II: Crohn's Disease
909
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
909
01:29Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
01:17Chronic Bowel Disorders: Introduction
721
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
721
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511